Dow Jones Newswires: Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints


Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer’s disease, failed to meet its primary endpoints.

The Swiss pharma company

said the drug failed to slow patients’ clinical decline and that the drug’s removal of beta-amyloid, a protein that builds up to make plaques in the brains of people with Alzheimer’s disease, was lower than expected.

The company said it would keep working on novel diagnostics and treatments for Alzheimer’s and said it would present at the Clinical Trials on Alzheimer’s Disease Conference.

Write to Pierre Bertrand at

Dow Jones Newswires: Rheinmetall to acquire Spanish ammunition maker Expal for $1.24 billion

Previous article

: Inflation will drop ‘significantly’ next year, Goldman Sachs economists forecast

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News